This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
The Lung Health Study, also identified as the Tobacco Education and Lung Health Study (TEAL), is a randomized, parallel-design phase 3 trial in smoking cessation. The registry lists an enrollment of 1,188 participants and two study arms evaluating behavioral tobacco-treatment strategies.
| Feature | Lung Health Study |
|---|---|
| Study name | Tobacco Education and Lung Health Study (TEAL) |
| Phase | Phase 3 |
| Condition | Smoking Cessation |
| Status | Recruiting |
| Design | Randomized, parallel |
| Masking | Single |
| Primary purpose | Treatment |
| Enrollment | 1,188 |
| Number of arms | 2 |
| Lead sponsor | Georgetown University |
| Start date | February 22, 2024 |
| Primary completion date | December 1, 2027 |
| ClinicalTrials.gov | NCT06290869 |
2. Clinical Question
The central statistical question is whether the randomized tobacco-treatment strategies produce different rates of biochemically verified 7-day point prevalence smoking abstinence at the 6-month assessment.
Population
Participants enrolled in a phase 3 study for the condition of smoking cessation. The registry lists planned enrollment of 1,188.
Intervention
Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention, described as behavioral.
Comparator
E-Referral to the Tobacco Quitline, described as behavioral.
Primary question
At the 6-month assessment, how do biochemically verified 7-day abstinence rates compare between the randomized study arms specified in the registry?
3. Trial Design
Phone-based tobacco treatment
- Phone-based Tobacco Treatment
- Nicotine Replacement
- Stepped Care Intervention
- Behavioral intervention
E-referral to tobacco quitline
- E-Referral to the Tobacco Quitline
- Behavioral intervention
The registry identifies the study as randomized with a parallel design and single masking. The design therefore supports a direct between-group comparison at the prespecified assessment point, with randomization providing the principal basis for causal comparison.
4. Trial Timeline
Study start
The registry lists February 22, 2024 as the study start date.
Recruiting
The ClinicalTrials.gov record identifies the study as recruiting.
Primary completion
The registry lists December 1, 2027 as the primary completion date.
5. Endpoints
| Endpoint | Time frame | Registry definition |
|---|---|---|
| Biochemically verified smoking abstinence- MHS vs. QL-E arms | 6-month assessment | Biochemically verified 7-day point prevalence abstinence rates, comparing the Health System (MHS) arm and the Quitline (QL-E) arm |
| Biochemically verified smoking abstinence--continued MHS arm vs Stepped Care | 6-month assessment | Biochemically verified 7-day abstinence rates between the Stepped Care arm and the Continued MHS arm |
What the endpoint measures
The primary endpoints are binary smoking-abstinence outcomes assessed at a defined time point. The key outcome is whether a participant meets the registry's definition of biochemically verified 7-day point prevalence abstinence at the 6-month assessment.
Point prevalence abstinence is a status measured at a specified assessment rather than a measure of continuous abstinence over the entire follow-up period. The biochemical verification component adds an objective verification procedure to the smoking-abstinence assessment.
6. Planned Analysis
No formal statistical analyses have been posted to ClinicalTrials.gov. The registry currently identifies the smoking-abstinence endpoints and their 6-month assessment time frame, but it does not report numerical treatment-effect estimates, confidence intervals, p-values, or event counts for these endpoints.
Primary statistical estimand
The clinically direct comparison is the difference in the proportion of participants meeting the biochemically verified 7-day abstinence definition at the 6-month assessment between randomized groups.
For a binary endpoint of this type, the principal analysis would typically compare the proportion abstinent in each randomized group. A risk difference expresses the absolute percentage-point separation between groups, while a risk ratio expresses the ratio of the two abstinence probabilities. A logistic-regression model can additionally be used when adjustment for prespecified baseline variables is appropriate.
The risk difference describes the absolute difference in the probability of biochemically verified abstinence at the 6-month assessment between two randomized groups.
The risk ratio describes the relative probability of meeting the abstinence endpoint in one randomized group compared with the other.
Because the registry provides no posted statistical-analysis results, there is currently no numerical treatment effect to interpret. The appropriate completed-trial analysis would report the abstinence proportion for each comparison, the corresponding effect estimate, its confidence interval, and the prespecified hypothesis test.
7. Statistical Methodology
Randomization and between-group comparison
Randomization is the central design feature for the causal comparison. If implemented as specified, assignment to the two parallel groups occurs independently of the eventual smoking-abstinence outcome. This allows differences in outcome rates between randomized groups to be interpreted as treatment-group differences under the trial's design and assumptions.
Binary endpoint analysis
The primary endpoints are expressed as abstinence rates. Each participant's outcome at the 6-month assessment can therefore be represented as a binary variable: meeting the biochemically verified abstinence definition or not meeting it.
| Statistical quantity | Question answered |
|---|---|
| Abstinence proportion | What proportion of participants met the endpoint in each group? |
| Risk difference | How many more or fewer participants per 100 met the endpoint in one group? |
| Risk ratio | How many times as common was endpoint achievement in one group? |
| Odds ratio | How do the odds of endpoint achievement compare between groups? |
| Confidence interval | How precisely is the treatment contrast estimated? |
| Hypothesis test | How compatible are the observed data with a prespecified null comparison? |
Confidence intervals
A confidence interval around a risk difference, risk ratio, or odds ratio quantifies statistical uncertainty in the estimated treatment contrast. Narrower intervals generally indicate greater precision, while wider intervals indicate greater uncertainty. The interval is not a range containing the true effect with a literal probability of 95% under the frequentist interpretation.
Adjusted analysis
If the statistical analysis plan prespecifies covariate adjustment, logistic regression or another appropriate binary-outcome model can estimate the treatment contrast while accounting for selected baseline variables. Adjustment should be prespecified rather than selected after observing which baseline characteristics appear imbalanced.
8. Statistical Methods Explained
Why is a binary analysis appropriate?
The primary endpoint is whether a participant achieves biochemically verified 7-day point prevalence abstinence at the 6-month assessment. That makes the endpoint naturally binary. The analysis therefore focuses on proportions and between-group contrasts in those proportions rather than on continuous means or time-to-event quantities.
What does a risk difference tell us?
A risk difference expresses an absolute treatment-group separation. For example, if two groups had abstinence probabilities of 0.30 and 0.20, the risk difference would be 0.10, or 10 percentage points. That example illustrates the method only; it is not an outcome from this study.
What does a risk ratio tell us?
A risk ratio compares probabilities rather than subtracting them. A value of 1 would represent equal abstinence probabilities between groups. Values above or below 1 indicate relative differences in the probability of meeting the endpoint.
Why is biochemical verification important statistically?
The registry specifies biochemical verification as part of the endpoint. This means the primary outcome is not simply an unverified self-reported smoking status. The verification procedure is part of the operational definition of the binary outcome and should be applied consistently when constructing the analysis population.
Why does the 6-month time frame matter?
The endpoint is defined at the 6-month assessment. The analysis therefore answers a time-specific question: the proportion meeting the abstinence definition at that assessment. It should not automatically be interpreted as evidence about continuous abstinence across all periods before or after 6 months.
Why does randomization matter for interpretation?
Randomization reduces systematic differences in treatment assignment and is the foundation for causal inference in the trial. It does not guarantee identical groups on every baseline characteristic, but it provides a principled basis for comparing outcomes according to randomized assignment.
9. Interpreting a Future Treatment Effect
If the completed analysis reports a risk difference, that estimate should be read as the absolute separation in the 6-month biochemically verified abstinence rate between the specified randomized groups. It does not describe the probability that an individual participant was personally caused to quit smoking by the intervention.
If a risk ratio or odds ratio is reported, it describes a relative contrast between groups. Relative measures should be interpreted alongside the underlying abstinence rates because the same relative effect can correspond to different absolute differences depending on the baseline event rate.
A confidence interval describes uncertainty around the estimated treatment contrast. A narrow interval indicates a more precise estimate than a wide interval. The width of the interval is affected by the number of participants, the observed event proportions, and the analysis method.
If a future analysis reports a p-value, it should be interpreted as a measure of compatibility between the observed data and the specified null hypothesis under the statistical model. It does not measure the size or clinical importance of the treatment effect.
10. The Two Primary Comparisons
The registry describes two primary endpoint comparisons. They should be treated as distinct statistical questions rather than combining them into a single outcome.
| Comparison | Outcome | Assessment |
|---|---|---|
| MHS vs. QL-E arms | Biochemically verified 7-day point prevalence abstinence | 6-month assessment |
| Continued MHS arm vs Stepped Care | Biochemically verified 7-day abstinence | 6-month assessment |
The existence of two primary comparisons raises an important statistical-design issue: the prespecified handling of multiple primary hypotheses determines how the overall type I error is controlled. The registry information does not report an alpha-allocation or multiplicity procedure for these comparisons.
11. Multiplicity and Multiple Primary Endpoints
When a trial has more than one primary hypothesis, the statistical interpretation depends on how those hypotheses are incorporated into the confirmatory testing strategy. If each hypothesis is tested independently at the same nominal significance level without adjustment, the probability of at least one false-positive conclusion can exceed the nominal level.
Multiple primary questions
The registry identifies two primary smoking-abstinence comparisons. Each addresses a separate treatment-group contrast.
Multiplicity control
A completed statistical analysis plan would ordinarily specify whether the primary comparisons share an overall type I error budget and, if so, how that budget is allocated.
Possible multiplicity strategies include hierarchical testing, alpha allocation, or other prespecified procedures. The choice of procedure affects the formal interpretation of p-values and confidence intervals. The registry does not report which approach was selected.
12. Missing Data and Smoking-Abstinence Outcomes
Binary smoking-abstinence endpoints create an important missing-data issue. A participant who does not provide the information needed to determine 6-month abstinence cannot automatically be treated as equivalent to a participant who is confirmed to be smoking unless that rule is prespecified by the analysis plan.
Common approaches in smoking-cessation trials can include conservative outcome classification rules, multiple imputation, or model-based methods, depending on the prespecified estimand and analysis plan. Each approach answers a somewhat different question and relies on different assumptions about the missing outcomes.
13. Analysis Population and Estimand
For a randomized treatment comparison, an intention-to-treat analysis generally preserves the comparison created by randomization by analyzing participants according to their randomized assignment. This is particularly important when participants discontinue or do not fully adhere to the assigned intervention.
For the Lung Health Study, the clinically meaningful estimand can be framed around the difference in the probability of biochemically verified 7-day point prevalence abstinence at the 6-month assessment under the randomized treatment strategies. The exact formal estimand, including handling of intercurrent events and missing assessments, would be defined by the trial's statistical analysis plan.
14. Masking and Outcome Assessment
The registry identifies the study as single masked. Masking can reduce the influence of knowledge of treatment assignment on selected aspects of trial conduct or outcome assessment, although the practical effect of masking depends on which individuals are masked and how the intervention is delivered.
The primary outcome includes biochemical verification, which provides an objective component to the ascertainment of smoking abstinence. Statistical interpretation still depends on consistent implementation of the endpoint definition across randomized groups.
15. Limitations and Interpretation Issues
- No posted numerical results: the registry currently does not provide treatment-effect estimates, confidence intervals, p-values, or event counts for the primary endpoints.
- Future primary completion: the registry lists December 1, 2027 as the primary completion date, so the study is described as recruiting rather than as a completed efficacy analysis.
- Two primary comparisons: the formal interpretation of statistical significance depends on the prespecified multiplicity strategy, which is not reported in the registry information available here.
- Binary outcome: the endpoint is measured at a specific 6-month assessment and should not automatically be interpreted as continuous abstinence throughout follow-up.
- Missing assessments: incomplete ascertainment can affect estimated abstinence rates, making the prespecified missing-data strategy important to interpretation.
- Analysis population: treatment-policy questions based on randomized assignment differ from analyses restricted to participants who adhered to treatment or completed assessment.
- Outcome verification: biochemical verification is part of the endpoint definition, so the final analysis depends on consistent ascertainment and classification of the verified outcome.
16. Why This Trial Matters Statistically
The Lung Health Study provides a useful teaching example of how a randomized behavioral intervention trial can be analyzed when the primary outcome is a binary clinical endpoint measured at a prespecified time point.
| Concept | How it appears in the Lung Health Study |
|---|---|
| Randomization | The study uses randomized allocation to two parallel arms. |
| Binary endpoint | Smoking abstinence at the 6-month assessment is defined as an outcome that can be classified as meeting or not meeting the endpoint. |
| Absolute effect | A risk difference can describe the percentage-point separation in abstinence rates between groups. |
| Relative effect | A risk ratio or odds ratio can describe the relative contrast in abstinence probabilities. |
| Confidence interval | Intervals quantify uncertainty around the estimated treatment contrast. |
| Hypothesis testing | A prespecified statistical test can evaluate the null comparison for each primary endpoint. |
| Multiplicity | Two primary comparisons require attention to overall type I error control. |
| Missing data | Incomplete 6-month assessments can affect the interpretation of observed abstinence rates. |
| Masking | The registry identifies the study as single masked. |
| Biochemical verification | The primary endpoint includes objective biochemical verification of smoking abstinence. |
17. Statistical Methods Explained in Practical Terms
Rate versus difference
The abstinence rate tells us how frequently the endpoint occurs in each arm. The risk difference then translates the comparison into an absolute percentage-point contrast.
Rate versus ratio
A risk ratio compares the two probabilities multiplicatively. It can be useful when the relative scale is clinically meaningful, but it should be read alongside the underlying rates.
Randomized analysis
Analyzing participants according to randomized assignment protects the causal comparison from some forms of treatment-selection bias introduced after randomization.
Missing outcomes
The way unavailable 6-month assessments are handled can change the estimated abstinence rate and therefore needs to be defined before the results are examined.
18. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The primary endpoints are binary abstinence outcomes assessed at 6 months. The natural statistical comparison is the difference between randomized groups in the probability of meeting the biochemically verified abstinence definition.
Clinical interpretation
The clinical meaning of the completed trial will depend on the observed abstinence rates, the absolute and relative treatment contrasts, their uncertainty, the handling of missing assessments, and the prespecified interpretation of the two primary comparisons.
19. What a Complete Results Analysis Should Report
Once the trial has a completed statistical analysis, a transparent results presentation for these endpoints would include several complementary quantities rather than a p-value alone.
| Result | Why it matters |
|---|---|
| Number analyzed in each randomized group | Defines the population contributing to the primary comparison. |
| Number meeting abstinence endpoint | Shows the observed event count underlying the rate. |
| Abstinence rate in each group | Provides the absolute outcome frequency. |
| Risk difference | Shows the absolute percentage-point treatment contrast. |
| Risk ratio or odds ratio | Shows a relative treatment contrast. |
| 95% confidence interval | Shows the precision of the estimated effect. |
| P-value | Addresses the prespecified hypothesis test, subject to the multiplicity framework. |
| Missing-data accounting | Shows how unavailable 6-month assessments were incorporated. |
| Analysis population | Clarifies whether the estimate follows randomized assignment or another analysis strategy. |
Presenting both absolute and relative measures is especially useful for a binary endpoint. The absolute abstinence rates provide the direct clinical context, while relative measures can describe the proportional separation between the randomized groups.
20. Record Summary
The Lung Health Study is a randomized phase 3 smoking-cessation trial with 1,188 planned participants and two parallel behavioral intervention arms. Its primary endpoints are biochemically verified 7-day point prevalence smoking-abstinence rates assessed at 6 months, with one comparison between the Health System and Quitline arms and another between the Continued MHS and Stepped Care arms.
Statistically, the trial is centered on a binary outcome rather than a time-to-event endpoint. The most direct completed analysis would therefore present the abstinence proportion in each randomized group together with absolute and relative treatment contrasts, confidence intervals, and prespecified hypothesis tests. Because two primary comparisons are identified, multiplicity control is an important component of the eventual confirmatory interpretation.
21. Sources
- ClinicalTrials.gov: NCT06290869 — Lung Health Study / Tobacco Education and Lung Health Study (TEAL).
Continue through the Clinical Biostats knowledge graph
Explore the broader Clinical Biostats collection of statistical tutorials, calculators, and clinical trial analyses.